藥物詳細合成路線

Name	Rofecoxib;MK-966;MK-0966;Vioxx
Chemical Name	4-[4-(Methylsulfonyl)phenyl]-3-phenylfuran-2(5H)-one
CAS	162011-90-7
Related CAS
Formula	C17H14O4S
Structure
Formula Weight	314.36273
Stage	撤市-2004
Company	Banyu (Originator), Merck & Co. (Originator), Merck Frosst (Originator), CollaGenex (Comarketer)
Activity/Mechanism	Acute Attacks of Migraine, Treatment of, Alzheimers Dementia, Treatment of , ANALGESIC AND ANESTHETIC DRUGS, Analgesic Drugs, Antiarthritic Drugs, Antimigraine Drugs, Cognition Disorders, Treatment of, Colorectal Cancer Therapy, Dental Agents, ENDOCRINE DRUGS, Gynecological Disorders, Treatment of , NEUROLOGIC DRUGS, Non-Opioid Analgesics, Oncolytic Drugs, Osteoarthritis, Treatment of, Rheumatoid Arthritis, Treatment of, Treatment of Dysmenorrhea, TREATMENT OF MUSCULOSKELETAL & CONNECTIVE TISSUE DISEASES, Cyclooxygenase-2 Inhibitors
Syn. Route	5

Route 1 the synthesis of rofecoxib can be performed by several different ways:1) the condensation of phenylacetic acid (i) with ethyl bromoacetate (ii) by means of triethylamine in thf yields 2-(phenylacetoxy)acetic acid ethyl ester (iii), which is cyclized to the hydroxyfuranone (iv) by means of potassium tert-butoxide in tert-butanol. the reaction of (iv) with triflic anhydride and diisopropylethylamine in dichloro-methane affords the corresponding triflate (v), which by reaction with libr in hot acetone yields the bromofuranone (vi). the condensation of (vi) with 4-(methylsulfanyl)phenylboronic acid (vii) by means of na2co3 and pd(ph3p)4 in hot toluene gives 4-[4-(methylsulfanyl)-phenyl]-3-phenylfuran-2(5h)-one (viii), which is finally oxidized with 2khso5.khso4.k2so4 (oxone).2) the intermediate (viii) can also be obtained by condensation of triflate (v) with boronic acid (vii) by means of na2co3 and pd(ph3p)4 in hot toluene.3) the intermediate (viii) can also be synthesized by the reaction of triflate (v) with tetramethylammonium chloride, giving the chlorofuranone (ix), which is then condensed with boronic acid (vii) as before. List of intermediates No. methyl 3-hydroxy-5-iodobenzoate (i) [(2r,3s,4s,5r)-5-(6-amino-2-fluoro-9h-purin-9-yl)-3,4-dihydroxytetrahydro-2-furanyl]methyl diethyl phosphate (ii) 2-methoxy-5-[(methylimino)methyl]phenol (vii) 5-([4-[(2s)-4-hydroxy-2-methyltetrahydro-2h-pyran-4-yl]-2-thienyl]sulfanyl)-1-methyl-1,3-dihydro-2h-indol-2-one (iii) (2s)-2-methyl-4-(5-sulfanyl-3-thienyl)tetrahydro-2h-pyran-4-ol (iv) 5-bromo-1-methyl-1,3-dihydro-2h-indol-2-one (v) methyl 3-[[6-(benzyloxy)-4-oxo-2h-chromen-3(4h)-ylidene]methyl]-4-hydroxybenzoate (vi) (3r,4r)-3-(5-amino-2-methoxybenzyl)-6-[(5,6-difluoro-1,3-benzothiazol-2-yl)methoxy]-3,4-dihydro-2h-chromen-4-ol (viii) 5-bromo-3-thiophenecarbaldehyde (ix) Reference 1:     sorbera, l.a.; rabasseda, x.; casta?er, j.; rofecoxib. drugs fut 1998, 23, 12, 1287. Reference 2:     tillyer, r.; desmond, r.; dolling, u.; marcune, b.; tschaen, d. (merck & co., inc.); process for making phenyl heterocycles useful as cox-2 inhibitors. wo 9608482 . Route 2 4) the oxidation of 4-(methylsulfanyl)acetophenone (x) with monoperoxyphthalic acid (mmpp) in dichloro-methane/methanol gives the corresponding sulfone (xi), which is brominated with br2/alcl3 in chloroform, yielding the expected phenacyl bromide (xii). finally, this compound is cyclocondensed with phenylacetic acid (i) by means of 1,8-diazabicyclo[5.4.0]undec-7-ene (dbu) and triethylamine in acetonitrile.5) reaction of [4-(methylsulfonyl)phenyl]phenylacetyl-ene (xiii) with co catalyzed by rh4(co)12 in thf at 100 c in a stainless steel autoclave at 100 atm pressure, followed by a chromatographic separation in a silicagel column to eliminate the undesired regioisomer. List of intermediates No. methyl 3-hydroxy-5-iodobenzoate (i) (5-bromo-3-thienyl)methanol (x) 4-(hydroxymethyl)-2-thiophenecarbonitrile (xi) 4-(bromomethyl)-2-thiophenecarbonitrile (xii) tert-butyl (3s)-1-[(5-cyano-3-thienyl)methyl]-2-oxopyrrolidinylcarbamate (xiii) Reference 1:     sorbera, l.a.; rabasseda, x.; casta?er, j.; rofecoxib. drugs fut 1998, 23, 12, 1287. Reference 2:     atkinson, j.g.; wang, z. (merck frosst canada inc.); stilbene derivs. useful as cyclooxygenase-2 inhibitors. ep 0788476; jp 1998507765; wo 9613483 . Reference 3:     ducharme, y.; gauthier, j.y.; prasit, p.; leblanc, y.; wang, z.; leger, s.; therien, m. (merck frosst canada inc.); phenyl heterocycles as cyclooxygenase-2 inhibitors. ep 0705254; ep 0739340; ep 0754687; ep 0822190; ep 0980866; jp 1997500372; jp 1997506631; jp 2000038375; us 5474995; wo 9500501; wo 9518799 . Reference 4:     hancock, b.; winters, c.; gertz, b.; ehrich, e. (merck & co., inc.; merck frosst canada inc.); compsns. for a once a day treatment of cyclooxygenase-2 mediated diseases. jp 1999512754; wo 9744028 . Route 3 6) the reaction of 4-bromothioanisole (xiv) with furan-2(5h)-one (xv) by means of tert-buli/cui in ethyl ether, followed by silylation with trimethylsilyl chloride gives 4-[4-(methylsulfanyl)phenyl]-2-(trimethylsilyloxy)-3,4-dihydrofuran (xvi), which is desilylated with palladium acetate in acetonitrile to afford the furanone (xvii). the iodination of (xvii) with i2 in pyridine yields 3-iodo-4-[4-(methylsulfanyl)phenyl]furan-2(5h)-one (xviii), which is condensed with phenylboronic acid (xix) by means of triphenylarsine and a pd catalyst in refluxing benzene, giving 4-[4-(methylsulfanyl)phenyl]-3-phenylfuran-2(5h)-one (viii), already described in scheme 1. finally, this compound is oxidized with monoperoxyphthalic acid magnesium salt in dichloromethane/methanol. List of intermediates No. (4ar,6r,7r,7as)-6-(6-amino-9h-purin-9-yl)-2,7-dihydroxytetrahydro-4h-2lambda(5)-furo[3,2-d][1,3,2]dioxaphosphinin-2-one (xix) (3r,4r)-3-(5-amino-2-methoxybenzyl)-6-[(5,6-difluoro-1,3-benzothiazol-2-yl)methoxy]-3,4-dihydro-2h-chromen-4-ol (viii) 4-[[(3s)-3-amino-2-oxopyrrolidinyl]methyl]-2-thiophenecarbonitrile (xiv) 7-methoxy-2-naphthalenesulfonyl chloride (xv) n-[(3s)-1-[(5-cyano-3-thienyl)methyl]-2-oxopyrrolidinyl]-7-methoxy-2-naphthalenesulfonamide (xvi) n-[(3s)-1-[(5-cyano-3-thienyl)methyl]-2-oxopyrrolidinyl]-7-methoxy-n-methyl-2-naphthalenesulfonamide (xvii) 4-[4-hydroxy-1-(4-hydroxyphenyl)-1-methyl-4,4-diphenylbutyl]phenol (xviii) Reference 1:     sorbera, l.a.; rabasseda, x.; casta?er, j.; rofecoxib. drugs fut 1998, 23, 12, 1287. Reference 2:     atkinson, j.g.; wang, z. (merck frosst canada inc.); stilbene derivs. useful as cyclooxygenase-2 inhibitors. ep 0788476; jp 1998507765; wo 9613483 . Reference 3:     hancock, b.; winters, c.; gertz, b.; ehrich, e. (merck & co., inc.; merck frosst canada inc.); compsns. for a once a day treatment of cyclooxygenase-2 mediated diseases. jp 1999512754; wo 9744028 . Route 4 7) the friedel-crafts condensation of thioanisole (xx) with acetyl chloride (xxi) by means of alcl3 in dichlorobenzene gives the corresponding acetophenone (x), which is oxidized with h2o2/wo4na2 to the ketosulfone (xi). the bromination of (xi) with br2 in acetic acid/48% hbr affords the phenacyl bromide (xii), which is condensed with phenylacetic acid sodium salt (xxiii) in dmf, giving the phenacyl ester (xxii). finally, this compound is cyclized by means of diisopropylamine in dmf. List of intermediates No. (5-bromo-3-thienyl)methanol (x) 4-(hydroxymethyl)-2-thiophenecarbonitrile (xi) 4-(bromomethyl)-2-thiophenecarbonitrile (xii) 2-hydroxy-5-iodobenzaldehyde (xx) 5-iodo-2-[(2-methoxyethoxy)methoxy]benzaldehyde; 5-iodo-2-[(2-methoxyethoxy)methoxy]benzaldehyde (xxi) [5-iodo-2-[(2-methoxyethoxy)methoxy]phenyl]methanol (xxii) 2-[[2-(bromomethyl)-4-iodophenoxy]methoxy]ethyl methyl ether; 2-(bromomethyl)-4-iodo-1-[(2-methoxyethoxy)methoxy]benzene (xxiii) Reference 1:     sorbera, l.a.; rabasseda, x.; casta?er, j.; rofecoxib. drugs fut 1998, 23, 12, 1287. Reference 2:     frey, l.f.; dolling, u.h.; desmond, r.; tillyer, r.d.; tschaen, d.m. (merck & co., inc.); process of preparing phenyl heterocycles useful as cox-2 inhibitors. wo 9800416 . Route 5 the friedel crafts acylation of thioanisole (i) with acetyl chloride (ii) and alcl3 in chloroform gives 4-(methylsulfanyl)acetophenone (iii), which is oxidized with monoperoxyphthalic acid (mmpp) in methanol/dichloromethane to yield 4-(methylsulfonyl)acetophenone (iv). the bromination of (iv) with br2 and alcl3 in chloroform affords 4-(methylsulfonyl)phenacyl bromide (v), which is finally cyclized by means of dbu and tea in acetonitrile to provide the target furanone derivative. List of intermediates No. methyl 3-hydroxy-5-iodobenzoate (vi) (5-bromo-3-thienyl)methanol (iii) 4-(hydroxymethyl)-2-thiophenecarbonitrile (iv) 4-(bromomethyl)-2-thiophenecarbonitrile (v) 2-hydroxy-5-iodobenzaldehyde (i) 5-iodo-2-[(2-methoxyethoxy)methoxy]benzaldehyde; 5-iodo-2-[(2-methoxyethoxy)methoxy]benzaldehyde (ii) Reference 1:     thérien, m.; gauthier, j.y.; leblanc, y.; leger, s.; perrier, h.; prasit, p.; wang, z.; synthesis of rofecoxib, (mk 0966, vioxx(r)) 4-(4-methylsulfonylphenyl)-3-phenyl-2(5h)-furanone), a selective and orally active inhibitor of cyclooxygenase-2. synthesis (stuttgart) 2001, 12, 1778.

來源:藥化網

作者:藥化小編

摘要:本文合成路線介紹的是藥物中文名羅非昔布；英文名Rofecoxib;MK-966;MK-0966;Vioxx；CAS[162011-90-7]

有機化學人才網，招聘求職的最佳選擇！